Arvinas, Inc
ARVNArvinas, Inc. is a biotechnology company specializing in the development of targeted protein degradation therapies. Founded to leverage innovative PROTAC (Proteolysis Targeting Chimera) technology, Arvinas focuses on creating treatments for various diseases, including cancer and neurodegenerative disorders. The company aims to address unmet medical needs by selectively degrading disease-causing proteins, offering potential for more effective and precise therapeutics.
Company News
Arvinas announced it has joined The Michael J. Fox Foundation's LRRK2 Investigative Therapeutics Exchange (LITE) program and Parkinson's Precision Medicine Initiative (PPMI) to advance ARV-102, its investigational PROTAC drug targeting LRRK2 for treating Parkinson's disease and progressive supranuclear palsy. The company plans to initiate Phase 1...
The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market w...
Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug r...
Arvinas, Inc. announced FDA approval of VEPPANU (vepdegestrant), the first-and-only FDA-approved PROTAC protein degrader, for treating estrogen receptor-positive advanced breast cancer with ESR1 mutations. The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026. The company also reported positive Phase 1 data for ARV-102 showing gr...
The FDA approved VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy developed by Pfizer and Arvinas for treating advanced breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial showed vepdegestrant reduced disease progression risk by 43% compared to fulvestrant, with median PFS of 5 months versus 2.1 months. Guardant Health's Gua...
